Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

Trial Identifier:	D8400C00001
Sponsor:	Alexion Pharmaceuticals, Inc.
Start Date:	July 2025
Primary Completion Date:	February 2029
Study Completion Date:	February 2029

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
FR	Le Kremlin-Bicêtre, FR, 94270
GB	Manchester, GB, M13 9WL
US, PA	Pittsburgh, PA, US, 15213
US, TN	Nashville, TN, US, 37212

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.